Pharm- Hepatitis Flashcards

(52 cards)

1
Q

Agents for HBV

A

Entacavir
Tenofovir
Peginterferon alfa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Agents for HCV

A
Simeprevir 
Daclatasvir
Sofosbuvir
Dasabuvir 
Ribavirin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Transmission of HAV

A

fecal-oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Transmission of HBV

A

sexual
parenteral
perinatal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Transmission of HCV

A

sexual
parenteral
perinatal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HBsAg

A

high levels occur during acute or chronic infection.

If found, the patient is infectious!

Normal immune response produces Ab’s to this Ag

We use this to make the HBV vaccine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

anti-HBs

A

Recover or immunity from HBV

Also arise after successful vaccination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Anti-HBc (total HBC core Ab)

A

Appears at onset of infection

Will persist for life

Indicates previous or ongoing infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

IgM anti-HBc

A

Recent (acute) infection <6mths

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HBeAg

A

High levels of HBV

Found during acute and chronic infection

Indicates viral replication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

HBeAb

A

Lower levels of HBV

Immune system may produce them after an acute infection or after a burst in viral replication.

Seroconversion (Ag –> Ab) is a good predictor of viral clearance in pt’s receiving treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Goal of HBV therapy

A

decrease morbidity and mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Goal of HCV therapy

A

Viral eradication (sustained viral response- SVR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Sustained viral response

A

viral eradication, the absence of HCV RNA by PCR for 12wks after completion of therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Advantages of IFNa compared to NA’s

A

Finite treatment duration
No resistance issues
Durable response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Disadvantages of IFNa compared to NA’s

A

Side effects

Cannot be used for pt’s with decompensated liver dz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Advantages of NA’s compared to IFNa

A

PO administration
Better tolerated
High response rate
Can be used for pt’s with decompensated liver dz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Disadvantages of NA’s compared to IFNa

A

?sustained response
Resistance
Side effects (peripheral neuropathy, lactic acidosis, hepatic steatosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

MOA of IFNa

A

cytokine! So inhibits everything…

Antiviral, immunomodulatory, and anti-proliferative actions. Inhibits viral penetration, translation, transcription, protein processing, maturation, and release. Enhanced phagocytic activity of macrophages and augmentation of proliferation/survival of cytotoxic T-cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

PK of peg-IFNa

A

“peg” = increased half life, slows clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

ADR’s of IFNa

A
flu-like symptoms 
transient increase in LFT's 
Neurotoxicity
Myelosuppresion
Fatigue
22
Q

C/I of IFNa

A

decompensated liver dz
Psych pt’s
Pregnancy

23
Q

DDI’s of IFNa

A

Theophylline

Methadone

24
Q

MOA of Entacavir

A

guanosine analog, inhibits DNA polymerase

25
Use of Entacavir
1st line treatment of HBV
26
ADR's of Entacavir
``` HA fatigue rash nausea dizziness ```
27
MOA of Tenofovir
adenosine analog, inhibits DNA polymerase
28
Use of Tenofovir
1st line treatment of HBV
29
ADR's of Tenofovir
N/V/D | decreased bone mineral density
30
NS3/4 Protease Inhibitors
Simeprevir | "-previr"
31
NS5A Protease Inhibitors
Daclatasvir | "-asvir"
32
NS5B RNA-Dependent RNA Polymerase Inhibitors
Sofosbuvir - Nucleot(s)ide Polymerase Inhibitors Dasabuvir - Non-Nucleoside Polymerase Inhibitor "-buvir"
33
MOA of Daclatasvir
binds N-terminus of NS5A, thereby inhibiting viral RNA replication and virion assembly
34
PK of Daclatasvir
CYP3A metabolism (C/I when on CYP3A inducers)
35
ADR's of Daclatasvir
Fatigue HA N/D increased lipase
36
MOA of Ledipasvir(-sofosbuvir)
inhibits NS5A protein necessary for viral replication; also acts as a chain terminator
37
ADR's of Ledipasvir(-sofosbuvir)
Insomnia!!! | Fatigue, HA, N/D, increased serum lipase
38
MOA of Ombitasvir-paritaprevir-ritonavir + dasabuvir
Ombitasvir- inhibits NS5A Paritaprevir- inhibits NS3/4A (polyprotein cleavage) Dasabuvir- inhibits RNA-dependent RNA polymerase Ritonavir- CYP3A inhibitor to increase plasma concentrations of the other drugs
39
PK of Ombitasvir-paritaprevir-ritonavir + dasabuvir
CYP metabolism | All are excreted in feces
40
ADR's of Ombitasvir-paritaprevir-ritonavir + dasabuvir
Pruritus/skin reactions Asthenia (generalized weakness) Elevated ALT Fatigue, HA, nausea, insomnia
41
MOA of Sofosbuvir
inhibits NS5B RNA dependent RNA polymerase, acts as a chain terminator
42
PK of Sofosbuvir
80% excreted in urine, substrate of P-glycoprotein
43
ADR's of Sofosbuvir
Anemia Neutropenia Myalgia Fatigue, HA, insomnia, pruritus, N/D, flu-like symptoms, weakness
44
MOA of Simeprevir
inhibits NS3/4A protease
45
PK of Simeprevir
CYP3A4 oxidative metabolism, excreted in feces
46
ADR's of Simeprevir
Pruritis/skin rash Nausea Myalgias Increased serum bilirubin
47
DDI's of Simeprevir
avoid with CYP inducers i.e. rifampin may increase concentration of other CYP3A4 substrates i.e. statins
48
MOA of Ribavirin
guanosine analog; inhibits initiation/elongation of RNA
49
Therapeutic uses of Ribavirin
``` Chronic HCV Influenza A and B Parainfluenza RSV Paramyxoviruses HIV-1 ```
50
ADR's of Ribavirin
hemolytic anemia depression fatigue, nausea, rash, insomnia
51
C/I's of Ribavirin
anemia ESRD ischemic vascular disease pregnancy (teratogenic)
52
CYP associations
Metabolized by CYP - Daclatasvir - Ombitasvir-paritaprevir-ritonavir plus dasabuvir - Simepravir CYP3A is inhibited by Ritonavir